NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) has released its financial results for the fourth quarter and year ended December 31, 2025. The company reported a net loss of $62.1 million, or $3.20 per diluted share, compared to a loss of $11.9 million, or $0.69 per diluted share in the same quarter of the previous year. This increase in loss is attributed to higher general and administrative expenses and stock-based compensation. Despite the losses, NeOnc highlighted significant operational achievements, including the completion of the Phase 1 dose escalation study for NEO212, which established a recommended Phase 2 dose of 610 mg, showing early signs of anti-tumor activity in heavily pretreated patients. The NEO100 Phase 2a study is fully enrolled, with interim data suggesting a 24% radiographic remission rate and a 44% six-month progression-free survival rate. The company also secured a $10 million PIPE financing from Cinctive Capital, enhancing its financial position to support ongoing clinical trials. Looking ahead, NeOnc plans to hold a Type B End-of-Phase 1 FDA meeting for NEO212 and anticipates preliminary data from the NEO100 Phase 2a trial in approximately five months. These developments position NeOnc for potential value creation for shareholders in the coming months.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.